Information de reference pour ce titreAccession Number: | 00005344-199704000-00016.
|
Author: | Kozai, Toshiyuki; Shimokawa, Hiroaki; Fukumoto, Yoshihiro; Kobayashi, Sei *; Owada, M. Koji +; Kadokami, Toshiaki; Ito, Akira; Kuwata, Kouichi; Egashira, Kensuke; Shiraishi, Tadayoshi ++; Kanaide, Hideo *; Takeshita, Akira
|
Institution: | Research Institute of Angiocardiology and Cardiovascular Clinic and *Division of Molecular Cardiology, Research Institute of Angiocardiology, Kyushu University School of Medicine, Fukuoka; +Institute of Molecular and Cellular Biology for Pharmaceutical Science, Kyoto Pharmaceutical University, Kyoto; and ++Takasago Research Laboratories, Research Institute, Kaneka Corporation, Takasago, Japan
|
Title: | Tyrosine Kinase Inhibitor Markedly Suppresses the Development of Coronary Lesions Induced by Long-Term Treatment with Platelet-Derived Growth Factor in Pigs In Vivo.[Article]
|
Source: | Journal of Cardiovascular Pharmacology. 29(4):536-545, April 1997.
|
Abstract: | Summary: Platelet-derived growth factor (PDGF) plays an important role in the development of coronary atherosclerosis. However, it remains to be examined what morphologic and functional changes are induced in vivo by the long-term treatment with PDGF itself or what pharmacologic interventions could suppress those changes in vivo. Our study was designed to address these points. We examined the effects of long-term treatment with PDGF on the porcine coronary artery in vivo. Under aseptic conditions, the proximal segments of the left porcine coronary artery were gently wrapped with cotton mesh absorbing sepharose beads either with or without recombinant human PDGF-AA or -BB. Two weeks after the operation, coronary hyperconstrictions to intracoronary serotonin or histamine were noted at the sites treated with PDGF-AA or -BB. Histologically, neointimal formation and geometric remodeling (reduction of the total vessel area) were noted at the PDGF-treated sites. These functional and histologic changes of the coronary artery induced by PDGF were markedly inhibited by cotreatment with ST 638, a specific inhibitor of tyrosine kinases. A Western blot analysis showed that ST 638 markedly suppressed the PDGF-induced tyrosine phosphorylations in the coronary segment. These results indicate that long-term treatment with PDGF induces neointimal formation, geometric remodeling, and vasospastic responses in vivo, for all of which, activation of tyrosine kinases is substantially involved.
(C) Lippincott-Raven Publishers
|
Author Keywords: | Platelet-derived growth factor; Tyrosine kinases; Restenosis; Vascular remodeling; Coronary vasospasm.
|
References: | 1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. Munro JM, Cotran RS. Biology of disease. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988;58:249-61.
3. Hannson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989;9:567-78.
4. Shimokawa H, Tomoike H, Nabeyama S, et al. Coronary artery spasm induced in atherosclerotic miniature swine. Science 1983;221:560-2.
5. Shimokawa H, Tomoike H, Nabeyama S, et al. Coronary artery spasm induced in miniature swine: angiographic evidence and relation to coronary atherosclerosis. Am Heart J 1985;110:300-10.
6. Egashira K, Tomoike H, Yamamoto Y, Yamada A, Hayashi Y, Nakamura M. Histamine-induced coronary spasm in regions of intimal thickening in miniature pigs; roles of serum cholesterol and spontaneous or induced intimal thickening. Circulation 1986;74:826-37.
7. Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 1974;71:1207-10.
8. Grotendorst GR, Chang T, Seppa HEJ, Kleinman HK, Martin GR. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol 1982;113:261-6.
9. Ferns GAA, Rains EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-32.
10. Nabel EG, Yang Z, Liptay S, et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 1993;91:1822-9.
11. Wang JYJ, McWhiter JR. Tyrosine kinase-dependent signaling pathways. Trends Cardiovasc Med 1994;4:264-70.
12. Helden CH, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1990;1:555-66.
13. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1[beta] induces coronary intimal lesions and vasospastic responses in pigs in vivo: the role of platelet-derived growth factor. J Clin Invest 1996;97:769-76.
14. Ito A, Shimokawa H, Kadokami T, et al. Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1[beta] in pigs in vivo. J Clin Invest 1995;96:1288-94.
15. Shiraishi T, Domoto T, Imai N, Shimada Y, Watanabe K. Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem Biophys Res Commun 1987;147:322-8.
16. Shiraishi T, Owada MK, Tatsuka M, Yamashita T, Watanabe K, Kakunaga T. Specific inhibitor of tyrosine-specific protein kinases: properties of 4-hydroxycinnamamide derivatives in vitro. Cancer Res 1987;49:2374-8.
17. Kita M, Ohmoto Y, Hirai Y, Yamaguchi N, Imanishi J. Induction of cytokines in human peripheral blood mononuclear cells by mycoplasmas. Microbiol Immunol 1992;36:507-16.
18. DiMario C, Gil R, Camenzind E, et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol 1995;75:772-7.
19. Andersen HR, Maeng M, Thorwest M, Falk E. Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury; insights from a porcine coronary (re)stenosis model. Circulation 1996;93:1716-24.
20. Pasterkamp G, Wensing PJW, Post MJ, Hillen B, Mali WPTM, Borst C. Paradoxical arterial wall shrinkage may contribute to luminal narrowing of human atherosclerotic femoral arteries. Circulation 1995;91:1444-9.
21. Owada MK, Iwamoto M, Koike T, Kato Y. Effects of vanadate on tyrosine phosphorylation and the pattern of polycoaminoglycan synthesis in rabbit chondrocytes in culture. J Cell Physiol 1989;138:484-92.
22. Hosang M, Rouge M, Wipf R, Eggimann B, Kaufmann F, Hunziker W. Both homodimeric isoforms of PDGF (AA and BB) have mitogenic and chemotactic activity and stimulate phosphoinositol turnover. J Cell Physiol 1989;140:558-64.
23. Siegbahn A, Hammacher A, Westermark B, Heldin CH. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest 1990;85:916-20.
24. Scott NA, Cipolla GD, Ross CE, et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 1996;93:2178-87.
25. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. Science 1986;232:87-90.
26. Ogawa H, Yasue H, Okumura K, et al. Platelet-derived growth factor is released into the coronary circulation after coronary spasm. Coron Artery Dis 1993;4:437-42.
27. Ito A, Shimokawa H, Nakaike R, et al. Role of protein kinase C-mediated pathway in the pathogenesis of coronary artery spasm in a swine model. Circulation 1994;90:2425-31.
28. Kadokami T, Shimokawa H, Fukumoto Y, et al. Coronary artery spasm does not depend on the intracellular calcium store but is substantially mediated by the protein kinase C-mediated pathway in a swine model with interleukin-1[beta] in vivo. Circulation 1996;94:190-6.
29. Fukumoto Y, Shimokawa H, Kozai T, et al. Tyrosine kinase inhibitor suppresses the (re)stenotic changes of the coronary artery after balloon injury in pigs. Cardiovasc Res 1996;32:1131-40.
30. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Medelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 1983;80:1337-41.
31. Ito A, Shimokawa H, Fukumoto Y, et al. The role of fibroblast growth factor-2 in the vascular effects of interleukin-1[beta] in porcine coronary arteries in vivo. Cardiovasc Res 1996;32:570-9.
32. Di Salvo J, Steusloff A, Semenchuk L, Satoh S, Kolquist K, Pfitzer G. Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun 1993;190:947-68.
33. Linder V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A 1991;88:3739-43.
34. Grant MB, Wargovich TG, Ellis EA, Cabellero S, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells: a potential treatment for restenosis? Circulation 1994;89:1511-7.
|
Language: | English.
|
Document Type: | Article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0160-2446
|
NLM Journal Code: | 7902492, k78
|
Annotation(s) | |
|
|